March 2025
Acelyrin Rebuffs Concentra’s Acquisition Bid, Reaffirms Commitment to Alumis Merger
Acelyrin, Concentra Biosciences, Alumis, Merger, Acquisition offer, Immunology, Biopharmaceuticals, All-stock transaction
Sofinnova Partners Secures €1.2 Billion for Life Sciences Innovation
Venture capital, biotech, medtech, digital medicine, industrial biotech, healthcare, sustainability
Atara Biotherapeutics Halves Workforce Amid FDA Setbacks for Key Therapies
Atara Biotherapeutics, layoffs, FDA clinical hold, Ebvallo, ATA3219, manufacturing issues
Australia Rejects Eisai’s Alzheimer’s Drug Leqembi
Leqembi, Eisai, Alzheimer’s disease, Australia, TGA, drug rejection
Pliant Therapeutics Discontinues Phase 2b/3 Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis Due to Safety Concerns
Pliant Therapeutics, bexotegrast, BEACON-IPF trial, idiopathic pulmonary fibrosis (IPF), safety concerns, clinical trial discontinuation
Novartis Licenses Kyorin’s Preclinical Chronic Hives Drug for $55M Upfront
Novartis, Kyorin Pharmaceutical, KRP-M223, chronic spontaneous urticaria, licensing deal, MRGPRX2 antagonist
Callio Therapeutics Debuts with $187M to Develop Next-Generation Multi-Payload ADCs for Cancer
Multi-payload ADCs, antibody-drug conjugates, oncology, HER2-targeted therapy, dual-payload technology, cancer treatment, biotechnology startup
Australia steadfast on rejection of Eisai, Biogen’s Alzheimer’s therapy Leqembi
Lecanemab, Eisai, Leqembi, Alzheimer ‘s disease, Decision, Presenile dementia, Australia
Novartis Secures Global Rights to Kyorin’s KRP-M223 for Allergic and Inflammatory Diseases
Novartis, Kyorin Pharmaceutical, KRP-M223, MRGPRX2 antagonist, chronic spontaneous urticaria, Dupixent, licensing agreement
Lexicon stumbles on second batch of mixed results for pain drug
Dosage, lexicon, Statistical Significance